Evidence map›Paper›PMID 40621476›Full record

ArticleMolecular therapy. Methods & clinical development2025

A sensitive sample preparation pipeline for adventitious virus detection using Oxford Nanopore sequencing.

Emmanuel K Tsinda, Charles A Swofford, James P B Strutt, José Sangerman, Raeuf Roushangar, Alexander Li, Lara M Gomez, Aidan N Bousquet, Caleb Neufeld, Jacqueline M Wolfrum and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Emmanuel K TsindaCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Charles A SwoffordCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
James P B StruttCritical Analytics for Manufacturing Personalized-Medicine, Singapore-MIT Alliance for Research and Technology, Singapore 138602, Singapore.
José SangermanCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Raeuf RoushangarCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Alexander LiCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Lara M GomezCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Aidan N BousquetCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Caleb NeufeldCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jacqueline M WolfrumCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jongyoon HanCritical Analytics for Manufacturing Personalized-Medicine, Singapore-MIT Alliance for Research and Technology, Singapore 138602, Singapore.
Rohan B H WilliamsCritical Analytics for Manufacturing Personalized-Medicine, Singapore-MIT Alliance for Research and Technology, Singapore 138602, Singapore.
Anthony J SinskeyCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Paul W BaroneCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Stacy L SpringsCenter for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent regulatory guidance now encourages the use of sequencing as an alternative adventitious agent testing assay to lengthy compendial

Indexed as

adventitious agent detectionbiomanufacturingcell therapylong read sequencingOxford Nanopore sequencingSISPAviral safety

Identifiers

PMID40621476
PMCPMC12229724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.